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Spinal cord injury (SCI) is a significant clinical challenge, and to date no effective treatment is available. 
Oligodendrocyte progenitor cell (OPC) transplantation has been a promising strategy for SCI repair. However, 
the poor posttransplantation survival and deficiency in differentiation into myelinating oligodendrocytes (OLs) 
are two major challenges that limit the use of OPCs as donor cells. Here we report the generation of an OL 
lineage population [i.e., pro-oligodendroblasts (proOLs)] that is relatively more mature than OPCs for trans-
plantation after SCI. We found that proOLs responded to lipopolysaccharide (LPS)-stimulated microglia con-
ditioned medium (L+M) by preserving toll-like receptor 4 (TLR4) expression, improving cell viability, and 
enhancing the expression of a myelinating OL marker myelin basic protein (MBP), compared to other OL 
lineage cells exposed to either LPS-stimulated (L+M) or nonstimulated microglia conditioned medium (L−M). 
When L+M-stimulated proOLs were intrathecally delivered through a lumbar puncture after a T10 thoracic con-
tusive SCI, they promoted behavioral recovery, as assessed by the Basso–Beattie–Bresnahan (BBB) locomotor 
rating scale, stride length, and slips on the grid tests. Histologically, transplantation of L+M proOLs caused a 
considerable increase in intralesional axon numbers and myelination, and less accumulation of invading mac-
rophages when compared with the vehicle control or OPC transplantation. Thus, transplantation of proOLs, 
preconditioned by L+M, may offer a better therapeutic potential for SCI than OPCs since the former may have 
initiated the differentiation process toward OLs prior to transplantation.
Key words: Microglial activation; Oligodendrocyte progenitor cells (OPCs);  
Pro-oligodendroblasts (proOLs); Spinal cord injury (SCI); Transplantation
INTRODUCTION
Myelin sheaths play an important role in maintain-
ing and protecting axons, providing trophic support to 
myelinated axons, and maintaining electrical impulse 
conduction in the central nervous system (CNS)1,2. Oli-
godendrocytes (OLs) are the cell type responsible for 
CNS myelin pro duction1,2. Primary demyelination in the 
CNS can be caused by genetic abnormalities, such as 
leukodystrophies3; by inflammatory damage and neuro-
degeneration, such as mul tiple sclerosis4,5, autoimmune 
encephalomyelitis6, and periventricular leukomalacia7; 
and by CNS trauma, such as spinal cord injury (SCI)8–10.
After SCI, OL cell death occurs at the site of injury 
and beyond8–11. Surviving OLs are postmitotic and can-
not remyelinate axons12. To replace OL loss after SCI, a 
promising strategy is to promote generation of new OLs 
through oligodendrogenesis. Indeed, progenitor cells are 
found throughout the CNS, and they give rise to myeli-
nating OLs during development and in adulthood13. 
After SCI, these progenitor cells proliferate robustly14–17 
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and differentiate into OLs particularly along the lesion 
border15,17–19. Importantly, oligodendrogenesis and remy-
elination can be found not only acutely but also chroni-
cally after SCI20. An alternative approach to replace 
the loss of OLs is to transplant OLs or their progenitors 
(OPCs) exogenously after SCI. Indeed, OPC transplanta-
tion has been a promising strategy for SCI repair; however, 
poor posttransplantation survival and deficiency in differ-
entiation into myelinating OLs are two major challenges21. 
Thus, identification of OL lineage cells that survive better 
than OPCs may offer promise in SCI repair. Eventually, the 
endogenous and exogenous OL repair strategies may be 
combined to promote a more complete recovery after SCI.
In the CNS, OL development can be divided into four 
distinct stages according to the temporal expression of cell 
surface markers and morphology: undifferentiated OL pro-
genitor cell (OPC; stage 1 or early OPC), pro-oligoden-
droblast (proOL; stage 2 or late OPC), differentiated preOL 
(preOL; stage 3 or immature OL), and mature OL (OL; 
stage 4)22,23. To initiate effective remyelination, precursor 
cells must switch from an essentially quiescent state to a 
regenerative phenotype1. This transition seems to be trig-
gered by factors derived from reactive microglia1,24.
Microglia dominate sites of CNS injury where they pro-
mote both injury and repair25. Lipopolysaccharide (LPS; or 
endotoxin) stimulation has been widely used for microglial 
activation26,27. Following CNS injury, depletion or inhibi-
tion of reactive microglia consistently confers neuroprotec-
tion and promotes functional recovery28,29. Paradoxically, 
the controlled activation or even augmentation of this 
response can enhance various indices of CNS repair (e.g., 
axon growth/sprouting, remyelination and delaying demy-
elination, promoting OPC proliferation30) or enhance preOL 
survival31. These controversial observations illustrate that 
microglial activation is not an all-or-none process but can 
vary depending on the stimulation context. Microglial 
responses to pathologic events are context dependent and 
adapt as the microenvironment changes. OL lineage cells 
at different developmental stages may respond differently 
to LPS-activated microglia stimulation and may undergo 
different fates, both in vivo32–35 and in vitro30,36.
In the present study, we sought to determine the 
responses of stage-specific OL lineage cells to toll-like 
receptor 4 (TLR4)-specific LPS-activated microglia stim-
ulation in vitro. We also determined whether intrathecal 
delivery of a selected population of these stimulated OL 
lineage cells (i.e., proOLs), after a contusive SCI, would 
be a better lineage than OPCs in promoting recovery.
MATERIALS AND METHODS
Animals and Reagents
All animals, including 35 adult male Wistar rats 
(weight: 230–250 g, age: 8 weeks) and 28 male neonatal 
Wistar rats were purchased from the animal center of the 
Academy of Military Medical Sciences of the Chinese 
PLA, P.R. China (AMMS). All animal care and surgical 
interventions were undertaken in strict accordance with 
the Public Health Service policies on humane care and 
the use of laboratory animals and with the approval of the 
institutional animal care and use committee (IACUC) and 
Institutional Biosafety Committee of the protocol (proto-
col No. 20100481475). Unless otherwise stated, all other 
chemicals used in this study were purchased from Sigma-
Aldrich (St. Louis, MO, USA).
Isolation of Microglia and Preparation of  
LPS-Stimulated Microglia Conditioned Medium
Primary mixed glial cells were prepared from neonatal 
rat neural progenitor cells (NPCs) by a shaking procedure 
according to the method of Chen et al. with some modi-
fications37. In brief, cerebral hemispheres were stripped 
free of meninges. After a digestion step, the cells were 
plated into cell culture flasks, and mixed cultures were 
grown in Dulbecco’s modified Eagle’s medium (DMEM) 
20S [DMEM, 4 mM L-glutamine, 1 mM sodium pyruvate, 
20% fetal bovine serum (FBS), 50 U/ml penicillin, and 
50 mg/ml streptomycin] at 37°C in 5% CO2 for 7 days 
with the medium changed every other day (Fig. 1A). 
Twelve hours after the last medium change, microglia 
were isolated by shaking the mixed glia-containing flasks 
for 2 h at 180 rpm. The microglia (purity >95%) were 
cultured in microglial culture medium [DMEM with 10% 
bovine serum albumin (BSA)] for 5 days (Fig. 1A).
For preparing LPS-stimulated microglia conditioned 
medium, the microglial culture medium was removed and 
replaced with microglial conditioned medium (contain-
ing 0.5% BSA) stimulated or not stimulated with TLR4-
specific LPS, abbreviated as L+M and L−M, respectively. 
LPS was derived from E. coli O111:B4 (Lot: tlrl-3pelps, 
solubility: 5 × 106 EU/ml in water) with a working con-
centration of 101–104 EU/ml (Biocompare, San Francisco, 
CA, USA). LPS was added at two concentrations: 0.1 
and 1.0 mg/ml. For the TLR4 inhibition group, a potent 
antagonist of LPS, Rhodobacter sphaeroides (RS; 50 
nmol/L; Invitrogen, San Diego, CA, USA), was added to 
the microglia culture along with LPS (LPS-RS). Twenty-
four hours later, the conditioned media were collected and 
filtered with a 0.45-mm filter and stored at −80°C until 
use. They were applied to OL lineage cell cultures with a 
1:3 ratio at defined stages of development (Fig. 1A).
Isolation of OPCs
After removing microglia from mixed glial cell culture, 
the flasks were subjected to shaking at 200 rpm for 22 h 
to separate OPCs from the astrocyte layer. The suspension 
was plated onto uncoated petri dishes for 2 × 2 h to fur-
ther remove residual contaminating microglia/astrocytes 
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by differential adhesion, and then the cells were seeded 
onto 200 mg/ml poly-L-lysine-coated coverslips at a den-
sity of 3 × 104 cells/coverslip and were allowed to prolifer-
ate for 2 days in proliferation medium (PM) that contains 
basal chemically defined medium [BDM; DMEM, 4 mM 
L-glutamine, 1 mM sodium pyruvate, 0.1% BSA, 50 mg/
ml Apo-transferrin, 5 mg/ml insulin, 30 nM sodium 
selenite, 10 nM D-biotin, and 10 nM hydrocortisone, 
supplemented with 10 ng/ml platelet-derived growth fac-
tor AA (PDGF-AA) and 10 ng/ml basic fibroblast growth 
factor (bFGF)]. Under the PM, OPCs proliferated and 
maintained their OPC status (Fig. 1A).
Preparation of Stage-Specific OL Lineage Cells
OPCs were the earliest stage of the OL lineage cells 
prepared in this study. They were maintained in the PM 
Figure 1. Schematic drawing of the experimental design and timeline. (A) In vitro isolation of microglia and oligodendrocyte (OL) 
lineage cells and treatments. (B) Summary of morphology and antigenic profile of different stages of OL lineage cells. (C) In vivo 
experimental design and timeline. Abbreviations: OPC, oligodendrocyte progenitor cell; proOL, pro-oligodendroblast; preOL, pre-
oligodendrocyte; A2B5, mouse monoclonal antibody to A2B5; PDGFaR, alpha receptor for platelet-derived growth factor; NG2, 
neural/glial antigen 2; O4, oligodendrocyte marker O4; GalC, galactocerebroside; MBP, myelin basic protein; MG, microglia; L−M, 
microglial conditioned medium that received no lipopolysaccharide (LPS) stimulation; L+M, lipopolysaccharide (LPS)-stimulated 
microglial conditioned medium; RS, Rhodobacter sphaeroides, an LPS inhibitor administered simultaneously with LPS; PM, pro-
liferation medium; DM, differentiation medium; BBB, Basso–Beattie–Bresnahan locomotor rating scale; PCR, polymerase chain 
reaction; wk, week.
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and were used directly (Fig. 1A). Under the differen-
tiating medium [DM; containing BDM supplemented 
with 15 nM triiodothyronine and 10 ng/ml ciliary neu-
rotrophic factor (CNTF), and 1× N-acetyl-cysteine (NAC)], 
OPCs were differentiated into proOLs (2–18 h), preOLs 
(36–72 h), and OLs (10 days) (Fig. 1A). OL lineage cells 
at different development stages (purity >90) showed 
different morphologies and expressed a combination of 
stage-specific markers (Fig. 1B).
LPS-Activated Microglia Stimulation of Stage-Specific 
OL Lineage Cells
To determine the effect of LPS-activated microglia 
stimulation on OL lineage cell survival, proliferation, 
and differentiation, stimulated or L+M (LPS: 0.1 or 1.0 mg/
ml), nonstimulated or L−M, LPS + RS (LPS 0.1 mg/ml + RS 
50 nmol/l), or basal (BS) control medium (PM or DM) 
was added to cultures of four different stages of OL lin-
eage cells for 4 h (OPC and proOL) or 24 h (preOL and 
OL) (Fig. 1A). OPCs and proOLs stimulated with L+M 
and L−M (>90 purity) were collected for in vivo trans-
plantation studies.
Cell Viability Assessments
Short-term viability (<72 h) was determined by try-
pan blue exclusion staining and live/dead assay accord-
ing to the manufacturer’s instructions (Life Technologies, 
Grand Island, NY, USA). Live cells were expressed as a 
percentage of the cells under basal untreated conditions, 
and dead cells were expressed as a percentage of the dead 
cells over total cells per field.
Cell survival/death rate in long-term cultures (>72 h) 
was determined by counting the number of pyknotic 
nuclei and intact nuclei stained with 4¢,6-diamidino-2-
phenylindole (DAPI), and the rate is calculated as the 
number of intact nuclei divided by the number of total 
nuclei (intact + pyknotic).
Cell viability was also examined using 3-(4,5-dime-
thylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
reduc tion assay following the manufacturer’s instruc-
tions38. Percent viability was calculated by comparing 
the experimental groups with the control group. Relative 
cell viability was determined by the amount of MTT con-
verted into formazan crystals and quantified as a percent-
age of control.
ELISA
The concentrations of tumor necrosis factor-a (TNF-a) 
and interleukin-6 (IL-6) in the culture media of cells 
treated as specified were measured using commercially 
available enzyme-linked immunosorbent assay (ELISA) 
kits according to the manufacturer’s instructions. Absorp-
tion at 450 nm was determined in a microplate reader 
(Tecan Group Ltd., Männedorf, Switzerland).
BrdU Labeling and Immunofluorescence Staining
Bromodeoxyuridine (BrdU) was added to cells at dif-
ferent time points and pulsed for 1 to 2 h to quantify cel-
lular proliferation. The BrdU-treated cells were fixed and 
acid treated, followed by immunostaining analysis with 
BrdU-specific antibody. We performed immunostaining 
using antibodies for BrdU (1:100; Roche, Indianapolis, 
IN, USA), Ki-67 (1:400; Abcam, Cambridge, MA, USA), 
A2B5 (1:100; Millipore, Billerica, MA, USA), platelet-
derived growth factor a receptor (PDGFaR; Chemicon, 
Darmstadt, Germany), nuclear Olig4 (O4; 1:100; Mil-
lipore), galactocerebroside (GalC; 1:100; Millipore), and 
myelin basic protein (MBP; 1:250). In all cases, nega-
tive controls were treated in the same way, but the pri-
mary antibody was omitted in each instance, confirming 
that staining was specific. Cells demonstrating double-
positive fluorescence were evaluated by counting five 
randomly selected high-power fields (×200) for each 
coverglass by two independent investigators under an 
inverted fluorescence microscope (OLYMPUS FV1200; 
Olympus America Inc., Center Valley, PA).
SCI Model and Cell Transplantation
We first determined functional efficacy of transplanted 
proOLs in three conditions: treated with LPS-stimulated 
microglia conditioned medium (L+M proOL; 1 mg/ml), 
microglia conditioned medium with no LPS stimulation 
(L−M proOL), or naive medium (naive proOL). In this 
experiment, adult male Wistar rats (weight: 230–250 g) 
aged 8 weeks were randomly divided into five groups (n = 
3/group): (1) laminectomy/sham control, (2) SCI + vehi-
cle [artificial cerebrospinal fluid (ACSF)], (3) SCI + L+M 
proOL, (4) SCI + L−M proOL, and (5) SCI + naive proOL. 
For cell preparation, the cell suspension was centrifuged 
at 200 × g for 6 min at 4°C. After the supernatant was 
removed, cells were resuspended at a final concentration 
of 5–10 × 106 cells/ml with ACSF. The cells were kept 
in a 0.5-ml microcentrifuge tube on ice until being used 
for transplantation.
For SCI, rats were anesthetized with sodium pentobar-
bital [50 mg/kg, intraperitoneal (IP) injection] and sub-
jected to a dorsal laminectomy at the 10th thoracic spinal 
level (T10) to expose the dorsal surface of the spinal 
cord39. Using an NYU spinal cord impactor, a 10-gauge 
rod was dropped from a vertical distance of 12.5 mm 
onto the exposed spinal cord. After the injury, muscles 
and subcutaneous tissues were sutured in layers, and the 
skin was stapled. Figure 1C illustrates the timeline and 
procedures of in vivo experiments.
For cell transplantation, 0.5 × 106 OPCs or stimulated 
proOLs, diluted in 40 ml of the ACSF, were injected 
intrathecally (IT) via lumbar puncture (L5/L6) at 4 h 
postinjury (PI). Control animals received laminectomy 
alone or SCI + vehicle injection. Animals received manual 
ACTIVATED PRO-OLIGODENDROBLASTS PROMOTE SCI REPAIR 2115
bladder expression twice daily and were inspected for 
weight loss, dehydration, and distress with appropriate 
veterinary care as needed.
In the second in vivo experiment, we tested the effi-
cacy of transplanted L+M proOLs, chosen from the first 
experiment, in their ability to promote histological and 
behavior recoveries. The transplantation of L+M proOLs 
was compared with that of OPCs, a well-accepted cell 
population that shows promise as donor cells for repair 
after SCI. In this experiment, adult male Wistar rats 
(weight: 230–250 g) aged 8 weeks were randomly 
divided into four groups (n = 5/group): (1) laminectomy/
sham control, (2) SCI + vehicle (ACSF), (3) SCI + L+M 
proOL, and (4) SCI + OPC. All cell preparation, SCI, and 
transplantation procedures followed those described in 
the first experiment.
Behavior Assessments
Open-field locomotion was evaluated by using the 
21-point Basso–Beattie–Bresnahan (BBB) locomotor 
rating scale40. Deficits in descending motor control were 
examined by the grid-walking test, which is a sensitive 
measure of the ability of animals to step rhythmically 
and coordinate accurate placement of limbs. Footprint 
analysis was performed at different time points using a 
procedure described previously41. Latency of withdrawal 
response to paw thermal stimulation was observed to 
evaluate thermal hyperalgesia.
Morphometric Analysis
Rats were euthanized and perfused with 4% buffered 
formalin, and spinal cords were extracted. Then T10 seg-
ments encompassing the lesion epicenter (about 3 mm) 
were fixed in 2% glutaraldehyde and 4% paraform-
aldehyde (PFA) for 2 h, osmicated for 3 h (1% OsO4), 
dehydrated, and embedded in plastic for toluidine blue 
staining according to standard procedures42. Semithin 
cross sections (1 mm) were made according to our exist-
ing protocol39. Every eighth section was collected and 
stained with toluidine blue for myelin and general mor-
phology. The G ratio and myelin thickness were mea-
sured in representative slides (five sections at the injury 
epicenter, 100 mm apart) by a neuropathologist who was 
blinded to the treatment groups. The axon diameter (mea-
sured to the inner border of myelin), G ratio (defined as 
the ratio of the axon diameter to the total diameter of the 
myelinated fiber), and myelin thickness (defined as total 
diameter of the myelinated fiber minus the axon diam-
eter) were quantified according to previously described 
methods43,44 from randomly chosen fields (four fields per 
animal, 20 × 30 mm/field at 100× magnification) within 
the lesion area from each animal and statistically com-
pared between groups using one-way analysis of variance 
(ANOVA) followed by Dunnett’s T3 post hoc test.
Reverse Transcription Polymerase 
Chain Reaction (PCR)
Total RNA was isolated with an RNeasy Mini kit 
(Qiagen, Valencia, CA, USA) and reverse transcribed 
using avian myeloblastosis virus (AMV) reverse tran-
scriptase. Generated cDNA was amplified by PCR with 
specific primers for TLR4 (5¢-TAC AGA AGC TGG TGG 
CTG TG-3¢, 5¢-CCA GAA CCA AAC GAT GGA CT-3¢) 
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(5¢-CCA CCC ATG GCA AAT TCC ATG GCA-3¢, 5¢-TCT 
AGA CGG CAG GTC AGG TCC-3¢). After 32 amplifica-
tion cycles, PCR products were analyzed on 1.5% agarose 
gels, stained with ethidium bromide, and subsequently 
visualized under UV light. To confirm the use of equal 
amounts of RNA in each experiment, all samples were 
checked for GAPDH mRNA expression.
Statistical Analysis
All data were presented as mean ± standard error of 
the mean (SEM) and were tested for homogeneity of 
variances. Differences within and between groups were 
analyzed using a two-way ANOVA followed by Fisher’s 
LSD post hoc test for repeated measurements with group 
and time as factors. Time-independent variables were 
compared with one-way ANOVA followed by post hoc 
Dunnett’s T3 or Bonferroni’s multiple comparison post-
test. Statistical analyses were performed using GraphPad 
Prism version 4 (Graph-Pad Software, San Diego, CA, 
USA). Differences were considered to be statistically sig-
nificant with a value of p < 0.05.
RESULTS
TLR4-Specific LPS Induces Microglial Activation
A classical tool used to activate microglial cells is LPS 
stimulation25,26. Within 24 h of LPS exposure, microglial 
cells were activated and released a number of proinflam-
matory substances including TNF-a and IL-6. In this 
study, LPS stimulation resulted in TNF-a (Fig. 2A) and 
IL-6 (Fig. 2B) release from activated microglia in a time-
dependent manner as tested by ELISA. TNF-a abundance 
peaked at 12 h after LPS exposure and remained signifi-
cantly high at 48 h. A significant increase in IL-6 release 
was observed at 12 h and peaked at 48 h (Fig. 2B). A very 
low level of TNF-a or IL-6 was detected in baseline con-
trol medium (BS) at all the time points that were examined 
(Fig. 2A and B). When RS, a TLR4 antagonist, was added 
to the microglia culture with LPS, it completely blocked 
LPS-induced microglial production of TNF-a (Fig. 2A) 
and IL-6 (Fig. 2B) at these time points. No significant 
difference in TNF-a or IL-6 expression was observed 
between the two concentrations of LPS (0.1 or 1.0 mg/ml) 
administered. Microglial activation was also confirmed 
by PCR analysis of TLR4 expression (Fig. 2C). After 
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Figure 2. LPS stimulation induced microglial response and TLR4 expression in OL lineage cells. Increased production of tumor necro-
sis factor-a (TNF-a) (A) and interleukin-6 (IL-6) (B) in microglial medium stimulated with two concentrations of lipopolysaccharide 
(LPS) (0.1 and 1.0 mg/ml). *p < 0.05. (C) Increased microglial toll-like receptor 4 (TLR4) expression was found in a time-dependent 
manner after LPS stimulation. Results are reported as the mean ± standard error of the mean (SEM) of three independent wells for 
each experimental condition. **p < 0.01. (D) Primary cultures of oligodendrocyte progenitor cells (OPCs) and pro-oligodendroblasts 
(proOLs) were either untreated or exposed to microglial conditioned medium treated with LPS (0.1 mg/ml, L+M) or without LPS (L−M) 
for up to 8 h followed by polymerase chain reaction (PCR) analysis. Extraction of total RNAs from cells pooled from three samples per 
group was prepared for the PCR study. Results are reported as mean ± SEM of three independent wells for each experimental condi-
tion. **p < 0.01. Abbreviations: BS, basal microglial medium; RS, Rhodobacter sphaeroides; LPS-RS (50 nmol/L, added to the 0.1 mg/
ml LPS-stimulated microglial medium); OL, oligodendrocyte; preOL, preoligodendrocyte; L−M, microglial conditioned medium that 
received no LPS stimulation; L+M, lipopolysaccharide (LPS)-stimulated microglial conditioned medium; GADPH, glyceraldehyde 
3-phosphate dehydrogenase; h, hour.
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exposure to LPS, LPS-specific TLR4 mRNA expression 
was significantly increased at 12 h after LPS stimulation, 
peaked at 24 h, and remained at a significantly high level 
at 48 h. No difference in TLR4 expression was observed 
between the two concentrations of LPS (Fig. 2C).
TLR4 mRNA Is Divergently Expressed in OL Lineage 
Cells in Response to Activated Microglia Stimulation
In contrast to microglia, direct stimulation of OL lin-
eage cells with LPS did not induce the release of cyto-
kines TNF-a and IL-6 (ELISA analysis, up to 48 h, data 
not shown). We then tested TLR4 mRNA expression 
in 2 OL lineage cell types, OPC and proOL, when they 
were either untreated or exposed to microglia conditioned 
medium treated without (L−M) or with LPS (L+M, 0.1 mg/
ml) (Fig. 2D). Naturally, only undifferentiated OL lin-
eage cells, such as OPCs and proOLs, but not differen-
tiated OLs, express TLR431. Addition of L−M or L+M to 
OPCs showed no difference between treatment groups, 
and between treatment groups and the baseline OPCs 
(Fig. 2D). In contrast, when exposed to L−M, proOLs 
showed a decrease in TLR4 expression in a time-dependent 
manner (Fig. 2D, lanes 6 and 10). Such a TLR4 decrease 
in proOLs could be significantly reversed by administrat-
ing L+M at both 4 and 8 h (Fig. 2D, lanes 5 and 9). These 
results indicate that TLR4 is expressed in proOLs and 
that its decrease can be reversed, at least in part, by LPS-
stimulated microglial activation.
TLR4 Is Expressed in the Injured Adult Rat Spinal 
Cord and in Animals Receiving Transplantation 
of Stimulated proOLs
We also determined the expression of TLR4 of the 
injured spinal cord at different time points or after trans-
plantation of OPCs or stimulated proOLs. Compared 
with the baseline group (0 day), TLR4 expression was 
significantly increased at 1 day post-SCI, peaked at 2–3 
days, and decreased but remained significantly high at 14 
days post-SCI (Fig. 3A). In the sham-operated control, 
the TLR4 mRNA level was very low. Increased levels of 
TLR4 mRNA were found in groups that received stimu-
lated proOL transplantation at 1 and 3 days (Fig. 3B). 
Such increases in TLR4, however, were significantly 
lower than the OPC and vehicle groups.
Figure 3. Time course of TLR4 expression following SCI or after transplantation of OPCs or stimulated proOLs. (A) Polymerase 
chain reaction (PCR) analysis shows the time course of toll-like receptor 4 (TLR4) mRNA expression after spinal cord injury (SCI). 
Values are expressed as mean ± standard error of the mean (SEM) of six groups, n = 3 per group. (B) TLR4 mRNA expression in 
the sham-operated control (CNT), SCI + stimulated pro-oligodendroblasts (proOL), SCI + oligodendrocyte progenitor cell (OPC), and 
SCI + phosphate-buffered saline (PBS) groups at 1 and 3 days post-SCI. Values are expressed as mean ± SEM of seven groups, n = 3 
per group. *p < 0.05; **p < 0.01; analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison posttest. Abbreviations: 
GADPH, glyceraldehyde 3-phosphate dehydrogenase.
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Figure 4. Different stages of oligodendrocyte (OL) lineage cells show selective vulnerability to LPS-stimulated microglial activa-
tion. Effects of lipopolysaccharide (LPS)-stimulated or nonstimulated microglial conditioned medium (L+M, microglia conditioned 
medium that received LPS stimulation, or L−M, microglial conditioned medium that received no LPS stimulation) or Rhodobacter 
sphaeroides (RS; an LPS inhibitor) on the viability of OL lineage cells at different developmental stages. Cultures received either 
basal microglia medium (basal, BS), L−M, or L+M (LPS: 0.1 mg/ml) for either 4 h [for oligodendrocyte progenitor cells (OPCs) and 
pro-oligodendroblasts (proOLs)] or 24 h [for preoligodendrocytes (preOLs) and OLs]. In addition, for the RS group, 50 nmol/L of RS, 
an LPS inhibitor, was added together with LPS to the L+M. Cell survival is expressed as a percentage of untreated cells in BS (A–D), 
and cell death is expressed as a percentage of dead cells over total cells per field (E–H). All data are expressed as mean ± standard 
error of the mean (SEM) (n = 3). (I–L) Effect of L+M or L−M on the differentiation of OL lineage cells. The newly appeared stage-
specific markers are expressed as the number of marker-specific cells/all cells per field. Cells were counted in five fields per coverslip 
(300–600 cells per field). *p < 0.05 versus BS; **p < 0.01 versus BS; p < 0.01 versus L−M. Abbreviations: GalC, galactocerebroside; 
MBP, myelin basic protein.
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Different OL Lineage Cells Show Different 
Vulnerabilities to Activated Microglial Stimulation
To better characterize the effects of activated micro-
glia stimulation on OL lineage cells, we determined their 
survival, proliferation, and differentiation using a live/
dead assay and a panel of OL developmental markers 
for OPCs (A2B5), proOLs (O4), preOLs (GalC), and 
OLs (MBP), respectively (Fig. 4). For OPCs, treatment 
with L+M and L−M significantly reduced OPC survival 
(Fig. 4A). Medium from both nonactivated (L−M) and 
activated (L+M) microglia strongly enhanced survival of 
more mature OL lineage cells including proOLs (Fig. 4B), 
preOLs (Fig. 4C), and OLs (Fig. 4D).
Medium from both nonactivated (L−M) and activated 
(L+M) microglia may also enhance the differentiation 
and maturation of more mature OL lineage cells. For 
example, immature OLs in basal medium remained less 
than 50% as undifferentiated GalC+ preOLs (Fig. 4K). 
L+M strongly accelerated preOL differentiation as evi-
denced by the presence of higher percentages of GalC+ 
preOLs. Notably, although L−M also increased GalC+ 
preOLs when compared to the nontreated control, the 
effect was weaker than that of the L+M group (Fig. 4K). 
These data suggest that microglial activation mediates 
protection of preOLs. For mature OLs, microglial acti-
vation enhanced primary OL viability as evidenced by 
the higher survival (Fig. 4D) and higher percentage of 
MBP+ mature OLs (Fig. 4L). Administration of LPS-RS 
failed to affect the viability and differentiation of OL 
lineage cells (Fig. 4).
Activated Microglial Stimulation Affects the  
Long-Term Survival, Proliferation, and Differentiation 
of OL  Lineage Cells at Different Developmental Stages
To test further the long-term effect of microglial activa-
tion on the viability, proliferation, and myelinating capa-
bility of OL lineage cells, we treated these cells with L+M 
and L−M at different OL stages (Fig. 1A). All cells were 
allowed to differentiate into the mature OL stage (e.g., 
approximately 15 days in vitro from the early OPC stage) 
and then were analyzed. Cell survival was determined 
with the MTT assay, which was used to assess mitochon-
drial function in living cells38. As shown in Figure 5A, in 
basal conditions, the survival rate of the OPC group was 
significantly lower than that of the mature OLs (dashed 
line, designated as 100%). In the presence of L+M or 
L−M, the survival rate of the OPC group remained signifi-
cantly low when compared to later stages of OLs treated 
with the same conditions (Fig. 5A). Importantly, only 
stimulated proOLs exposed to L+M showed the greatest 
survival compared to those exposed to L−M or compared 
to other OL lineage cells exposed to either L+M or L−M 
(Fig. 5A). Furthermore, stimulated proOLs exposed to 
L+M showed the greatest staining for MBP, a myelinating 
OL marker, than any other cell stages exposed to L+M or 
L−M (Fig. 5B).
To determine the long-term effect of activated micro-
glial stimulation on proliferation of OL lineage cells, both 
Ki-67+ staining (Fig. 5C) and BrdU incorporation (Fig. 5D) 
assays were used. OPCs cultured in the basal medium (BS) 
containing no microglia conditioned medium were used as 
a control (100%). We found that exposure to L+M and L−M 
inhibited proliferation of OPCs (~75–80% of the control) 
(Fig. 5C). The proliferation rate of proOLs was further 
reduced in the presence of L+M and L−M compared to that 
of OPCs. Almost no proliferation was observed in both 
preOL and OL cells when exposed to L+M or L−M (Fig. 
5C). BrdU incorporation assay further confirmed results 
observed by Ki-67 staining (Fig. 5D).
Effect of Activated Microglia Stimulation on the 
Morphology of OL Lineage Cells at Different 
Developmental Stages
OL lineage cells at different developmental stages can 
be detected by a combination of stage-specific markers 
(shown in Fig. 1B). OPCs were double labeled with 
PDGFaR and A2B5 and showed typical bi- or tripolar 
morphology (Fig. 6A and B). ProOLs were double labeled 
with PDGFaR and O4, contained a few short processes, 
and were morphologically simple (Fig. 6C and D). PreOLs 
were double labeled with GalC and O4 and showed a mul-
tipolar morphology (Fig. 6E and F). Mature OLs were 
double labeled with MBP and O4 and contained membrane 
sheets or lacy processes, which were extensively ramified 
(Fig. 6G and H). In general, OL lineage cells stimulated 
with L+M showed similar morphological characteristics to 
control culture without microglial conditioned medium.
Transplantation of Stimulated proOLs Improves 
Locomotor Function After a Contusive SCI
We first compared the efficacy of three kinds of 
proOLs stimulated with LPS-activated microglia (L+M 
proOL), nonactivated microglia (L−M proOL), or no 
stimulation (naive proOL) following contusive SCI. The 
BBB open-field test demonstrated that animals receiv-
ing L+M proOLs had significantly improved locomo-
tor recovery at and beyond 4 weeks PI compared to the 
vehicle, L−M proOL, and naive proOL groups (Fig. 7A). 
The L+M proOL group, therefore, was selected for the 
second experiment comparing its efficacy with OPCs, 
which have been tested previously for transplantation 
after SCI10,21,45,46.
When comparing the efficacy of L+M proOLs with 
OPCs, combined motor performance was evaluated. The 
BBB open-field test demonstrated that animals receiving 
stimulated proOLs showed significantly greater recov-
ery at and beyond 4 weeks PI compared to the vehicle 
and OPC groups (Fig. 7B). Footprint analysis at 5 weeks 
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Figure 5. Effect of LPS-stimulated microglial conditioned medium on the proliferation and survival of different stages of oligoden-
drocyte (OL) lineage cells. (A) Long-term survival assessment of OL lineage cells treated with or without lipopolysaccharide (LPS)-
stimulated microglial conditioned medium (L+M, microglia conditioned medium that received LPS stimulation, and L−M, microglial 
conditioned medium that received no LPS stimulation, respectively). The design can be seen in Figure 1A. Mature OLs with no 
treatment served as a control (100%, dashed line). (B) Myelinating capacity of OL lineage cells treated with L+M or L−M at differ-
ent stages. (C) Ki-67+ staining shows the effect of L+M or L−M on oligodendrocyte progenitor cells (OPCs), pro-oligodendroblasts 
(proOLs), preOL, and OL proliferation compared with OPCs cultured in the basal microglia medium (BS; considered as 100%). 
(D) Bromodeoxyuridine (BrdU) incorporation assay confirmed the Ki-67+ staining result. BrdU was added during the last 16 h of cul-
ture. The data represent the percentage of BrdU incorporation in L+M- and L−M-treated cells compared to that in the BS (considered as 
100%). *p < 0.05; **p < 0.01. Two-way analysis of variance (ANOVA) followed by Fisher’s LSD post hoc test. Abbreviations: MBP, 
myelin basic protein; PCR, polymerase chain reaction.
FACING PAGE
Figure 6. Effect of lipopolysaccharide (LPS)-stimulated microglial conditioned medium on morphology of OL lineage cells. Each 
oligodendrocyte (OL) lineage cell type was identified with two stage-related markers. (Rows A and B) Oligodendrocyte progenitor 
cells (OPCs) were double labeled with platelet-derived growth factor a receptor (PDGFaR) and mouse monoclonal antibody to A2B5 
(A2B5). The cells show typical bi- or tripolar morphology. (Rows C and D) Pro-oligodendroblasts (proOLs) were double labeled with 
PDGFaR and oligodendrocyte marker O4 (O4). These cells contain a few short processes and are morphologically simple. (Rows E 
and F) PreOLs were double labeled with galactocerebroside (GalC) and O4. These cells show a multipolar morphology. (Rows G and 
H) Mature OLs were double labeled with myelin basic protein (MBP) and O4. Mature OLs contain membrane sheets or lacy processes, 
which are thicker than those of preoligodendrocytes (preOLs). Their processes are extensively ramified. In general, stage-specific OL 
lineage cells showed similar morphological characteristics in control culture medium (A, C, E, G) or in lipopolysaccharide (LPS)-
stimulated microglial conditioned medium (L+M; B, D, F, H). Abbreviations: L+M, lipopolysaccharide (LPS)-stimulated microglial 
conditioned medium; L−M, microglial conditioned medium that received no LPS stimulation; CNT, toll-like receptor 4 (TLR4) mRNA 
expression in the sham-operated control. Scale bars: 20 mm.
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post-SCI showed significant differences in paw length 
between the sham and OPC or vehicle group but no dif-
ference between the sham and stimulated proOL group 
(Fig. 7C). In the stimulated proOL group, the stride 
length was significantly improved (Fig. 7D), and the 
number of slips on the grid was significantly reduced 
compared to the OPC and vehicle groups (Fig. 7E). The 
hot plate test revealed that the withdraw latency was 
significantly reduced in all three SCI groups compared 
with the sham group that received only laminectomy 
(Fig. 7F). These results indicate that transplantation of 
stimulated proOLs, but not OPCs or vehicle, improved 
locomotor, but not sensory, recovery after SCI.
Transplantation of Stimulated proOLs Increases 
Intralesional Axon Numbers and Myelination After 
a Contusive SCI
To determine whether transplantation of L+M proOLs 
improved tissue repair, we examined cross sections of 
the injury epicenter after toluidine blue staining. In all 
groups, lesions were found to be confined in the dorso-
lateral area of the spinal cord, leaving the ventrolateral 
area largely spared. We found that the SCI + L+M proOL 
group (Fig. 8, right column) contained the greatest 
amount of intralesional axons and myelin at the lesion 
epicenter compared to the SCI + vehicle (Fig. 8, left col-
umn) or SCI + OPC group (Fig. 8, middle column). In 
fact, in both the SCI + vehicle and SCI + OPC groups, the 
lesion epicenter was filled with numerous macrophages. 
Figure 9B–D further shows the presence of numer-
ous debris-laden macrophages in the lesion epicenter 
in the SCI + vehicle (Fig. 9B) and SCI + OPC (Fig. 9C) 
groups and the presence of numerous axons and myelin 
in the lesion epicenter of the SCI + L+M proOL group 
(Fig. 9D). Moreover, the SCI + L+M proOL group sig-
nificantly decreased the G ratio (Fig. 9E) and increased 
myelin thickness (Fig. 9F) compared to the vehicle and 
OPC groups. Collectively, these results suggest that acute 
transplantation of activated microglia-stimulated proOLs 
is a more superior repair strategy than no transplantation 
or transplantation of OPCs in enhancing intralesional 
axon number and myelination. The histological results 
are also in strong agreement with the behavioral results 
described earlier.
DISCUSSION
One consequence of SCI is OL cell death and demy-
elination contributing to functional deficits. Here we 
report that L+M proOLs were more resistant to cell death 
than OPCs in vitro and that intrathecal delivery of L+M 
proOLs increased intralesional axons and myelin and 
markedly improved behavioral recovery following a con-
tusive SCI in adult rats. To our knowledge, this is the first 
time that L+M-stimulated proOLs were transplanted in a 
SCI model and that such transplantation resulted in histo-
logical and functional improvements after SCI.
Activated Microglia Stimulation Has Divergent 
Effects on Stage-Specific OL Lineage Cells
In this study, we established the isolation and char-
acterization of OL lineage cultures at different devel-
opmental stages, allowing us to compare their viability, 
proliferation, differentiation, and expression of myelin-
associated proteins in the presence or absence of acti-
vated microglia stimulation. We noted divergent effects 
of LPS-induced microglia conditioned medium or L+M 
on viability of OL lineage cells. While reducing the 
survival of early OPCs, L+M increased the survival of 
more mature OL lineage cells, including the late OPCs 
or proOLs. It should be noted that in both cases L+M 
was able to reverse the baseline state of OL lineage cells 
by reducing early OPC proliferation and rescuing more 
mature OL lineage cells from death. In the literature, stud-
ies examining the effect of reactive microglia on the sur-
vival of OL lineage cells have yielded conflicting results. 
For example, LPS-induced reactive microglia have been 
reported to augment30 or attenuate36 OPC proliferation or 
are toxic to them in vitro and in vivo47. Our data indicate 
that activated microglia-induced effects on OPCs may be 
dependent on the kind of microglial activator used, the 
factors released from the activated microglia48, and the 
stages of cell maturation.
In this study, we show, for the first time, that activated 
microglia stimulation enhanced proOL survival, differ-
entiation, and expression of myelin-associated proteins. 
Although both nonactivated and LPS-activated microglia 
equally reduced cell death during OL lineage cell differ-
entiation, L+M stimulation at the proOL stage was signifi-
cantly more effective than other OL stages in supporting 
cell survival and differentiation. Importantly, cells stimu-
lated by activated microglia at the proOL stage increased 
the number of live cells by approximately 30–40% com-
pared with the basal, untreated OPCs. This observation 
indicates that O4+ proOLs benefit from the presence of 
reactive microglia and presumably resist the deleterious 
effects that the activated microglia exert on early OPCs. 
Our results are in agreement with some previous studies 
showing that more mature OLs are more resistant than 
OPCs to a wide variety of insults, including inflamma-
tion, oxidative stress, and elevated glutamate levels31,49. 
Though the mechanism needs further investigation, our 
data indicate that normally occurring OL death may reflect 
a competition for survival signals from factors released 
by activated microglia that are limited in amount or avail-
ability. This is partially in line with previous studies that 
most OLs produced in the optic nerve are normally lost 
within a brief period after they are generated38,50,51. We 
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Figure 7. Transplanted L+M proOLs improved motor recovery after acute contusive SCI. (A) Comparison of Basso–Beattie–Bresnahan 
(BBB) locomotor rating scale among five treatment groups. The L+M proOL transplantation group showed significant improvement 
of BBB score than the vehicle, L−M proOL, and naive proOL groups. *p < 0.05; two-way analysis of variance (ANOVA) followed by 
Fisher’s LSD post hoc test. (B) Comparison of BBB locomotor rating scale among four treatment groups. The SCI + L+M proOL group 
showed significant improvement of BBB score than the SCI + vehicle and SCI + OPC groups. *p < 0.05; two-way ANOVA followed 
by Fisher’s LSD post hoc test. (C, D) Footprint analysis at 5 weeks post-SCI showed no difference in paw length between the sham 
and SCI + proOL groups but showed significant differences between the sham and SCI + OPC or SCI + vehicle groups (C). Significant 
increase in stride length of hindlimbs was found in the SCI + proOL group compared to the SCI + OPC or SCI + vehicle group (D). 
(E) Grid walking analysis at 4 weeks post-SCI. The number of hindpaw foot drop errors on the grid per run was significantly reduced 
in the SCI + proOL group compared to the SCI + OPC or SCI + vehicle group. (F) Withdraw response in the 53°C hot plate test at 6 
weeks post-SCI. There was a significant difference between the sham and the three treatment groups. However, no difference was 
found between the three treatment groups. *p < 0.05; **p < 0.01; one-way ANOVA followed by post hoc Dunnett’s T3. Abbreviations: 
L+M, lipopolysaccharide (LPS)-stimulated microglial conditioned medium; L−M, microglial conditioned medium that received no 
LPS stimulation; proOL, pro-oligodendrites; LH, left hindlimb; OPC, oligodendrocyte progenitor cell; RH, right hindlimb; SCI, spinal 
cord injury.
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conclude that L+M-stimulated proOLs are more resistant 
than early OPCs to a wide variety of insults.
ProOLs May Respond to TLR4-Specific LPS Through 
a Direct and an Indirect Mechanism
TLR4-specific LPS does not affect other TLRs in 
vitro31. LPS binds to TLR4-myeloid differentiation fac-
tor 2 complexes (TLR4-MD2) on host–cell surfaces and 
promotes their dimerization. This initiates intracellular 
signaling52. In this study, microglial activation was evi-
denced by the expression of TLR4 mRNA and the release 
of proinflammatory cytokines in a time-dependent man-
ner after LPS stimulation. The releasing of TNF-a and 
IL-6 is TLR4 dependent since blocking TLR4 with 
LPS-RS can completely block such release.
The expression of TLR4 mRNA by both OPCs and 
proOLs suggests that these cells were directly responsive 
to LPS. In vitro, TLR4 expression in stimulated proOLs 
was significantly higher than that in nonstimulated coun-
terparts. In vivo, TLR4 was activated following SCI26,53, 
but its expression in the stimulated proOL transplanta-
tion group was significantly lower than in the OPC or 
vehicle control groups. These data suggest that TLR4 
may play a role in OPC proliferation and differentiation. 
Additionally, Schonberg et al. showed that intraspinal 
macrophages could be activated by the TLR4 ligand, 
Figure 8. Transplantation of L+M proOLs increased intralesional axon number and myelination after acute contusive SCI at T10. 
(A–C) Images of toluidine blue-stained semithin transverse sections show the injury epicenter of different treatment groups. Pro-
oligodendrites were preconditioned with lipopolysaccharide (LPS)-stimulated microglia (L+M proOLs). In all groups, lesions were 
found to be in the dorsal area of the spinal cord. (D–F) High magnifications of boxed areas in (A)–(C) show the lesion sites filled with 
cellular structures and myelinated axons. (G–I) At even higher magnifications of boxed areas in (D)–(F), numerous macrophages, 
engulfed with cellular debris (G, arrows), and degenerating myelin profiles (G, dashed arrows), acellular spaces (H, *), and myelinated 
axons (I) were found in different treatment groups (I). Dashed arrows in (I) illustrate newly formed thin myelin surrounding axons 
within the lesion site after spinal cord injury (SCI). Scale bar: 200 mm (A–C), 50 mm (D–F), 15 mm (G–I). Abbreviations: OPC, oli-
godendrocyte progenitor cell.
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which caused a local increase in IL-1b and CNTF and 
induced NG2+ cell proliferation and oligodendrogen-
esis54. Furthermore, the beneficial effect of macrophages/
microglia was also reported in a contusive SCI model, 
where recovery was impaired in TLR2 and TLR4 null 
mice55. Finally, LPS-stimulated microglial activation via 
TLR4 improved remyelination, supporting the importance 
of TLR signaling in repair processes24. Thus, the effect 
of LPS on the transplanted proOLs after SCI could be 
mediated directly through TLR4 expression on proOLs 
or indirectly through activated microglia stimulation of 
proOLs prior to transplantation56, or both.
Microglial Activation-Stimulated proOLs Promote 
Tissue Repair and Behavioral Recovery
In the present study, we first determined that trans-
plantation of L+M proOLs, rather than L−M proOLs, or 
naive proOLs, improved locomotor recovery in a contu-
sive SCI model, as assessed using BBB locomotor rating 
scales. We then used comprehensive behavior and histo-
logical assessments to determine the efficacy of trans-
planted L+M proOLs in the same model and compared 
that with the vehicle and OPC transplantation groups. 
The OPC group was used as a transplantation control 
because these cells have shown promise for cell-based 
repair of SCI10,21,45,46. We found that intrathecal delivery of 
L+M proOLs resulted in significantly greater behavioral 
recovery in BBB locomotor rating scale, stride length, 
and slips on the grid assessments than the vehicle and 
OPC groups. Histologically, transplantation of stimulated 
proOLs after acute SCI caused a considerable increase 
in intralesional axon number and myelination, and less 
accumulation of macrophages when compared with the 
nonstimulated OPCs. Thus, proOLs may be a better 
Figure 9. Transplantation of L+M proOLs increased intralesional axon number and myelination. (A–D) Myelinated axons (A), mac-
rophages (B, solid arrows), degenerating myelin debris (B, dashed arrows), myelinated axon fascicles (C, dashed arrows), debris-filled 
macrophages (C, solid arrows), and thin myelinated axons (D, dashed arrows) were found in the sham (A) and different treatment 
groups (B–D). Notably, Schwann cells were frequently found to myelinate axons (D, solid arrow). (E, F) The G ratio (E) and myelin 
thickness (F) are shown. **p < 0.05; analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison posttest. Three rats 
from each group were analyzed, and a minimum of 500 axons were measured from each rat. Abbreviations: OPC, oligodendrocyte 
progenitor cell; proOL, pro-oligodendroblast; L+M, lipopolysaccharide (LPS)-stimulated microglial conditioned medium.
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source of OL lineage cells than OPCs for transplantation 
in promoting repair and recovery after SCI. We did not 
consider using late-stage OLs (preOLs or mature OLs) 
for transplantation because these cells are postmitotic, 
nonmigratory, and unable to remyelinate upon transplan-
tation into lesions22,23,57. Since our grafted L+M proOLs 
were not prelabeled, it was difficult to determine the fate 
of these cells in vivo after being IT delivered. Our histo-
logical and functional assessments, both blinded, indicate 
that these cells played a functional role. However, further 
studies need to be conducted to determine their survival, 
migration, and differentiation in this model using prela-
beled proOLs.
Comparing with direct transplantation of OPCs, induc-
tion of OPCs to proOL in vitro prior to transplantation, as 
presented here, may be more advantageous since these 
cells have already initiated the differentiation process 
toward more mature OLs, and such process, when initi-
ated, may be less affected by the host microenvironment. 
It is conceivable that without fully differentiating, grafted 
OPCs cannot exert their myelination function. One reason 
for the lack of full differentiation after OPC transplanta-
tion is that reactive astrocytes may inhibit differentiation 
of grafted OPCs into OLs with concurrent promotion of 
astrocyte differentiation45. For OPCs to differentiate into 
mature OLs, the first and critical step is to initiate their 
differentiation into OL lineage rather than into astrocytes. 
Our results indicate that transplantation of proOLs is 
more advantageous than that of OPCs, since the former 
have already initiated the myelinating process and, there-
fore, will likely continue to mature after transplantation.
CONCLUSIONS
The current study reports a promise of intrathecal 
delivery of proOLs, stimulated by activated microglia, 
into a clinically relevant, contusive SCI model. Such an 
approach may offer a promising therapeutic potential to 
promote tissue repair and functional recovery after SCI.
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